Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone in Sporadic Inclusion Body Myositis
NCT03440034Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- May 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pioglitazone in sporadic inclusion body myositis (sIBM), sponsored by Johns Hopkins University. Primary endpoint: Change from baseline in Peroxisome proliferator-activated receptor gamma coactivator 1-alpha target gene expression at 32 weeks. Started May 2018; status: completed.
02
Drugs
pioglitazone
03
Conditions
sporadic inclusion body myositis (sIBM)
Beyond the preview
Go deeper on NCT03440034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03440034.